Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Swayed By Industry Opposition To 'Intended Use' Rule, FDA Definitively Delays Implementation

Executive Summary

US FDA is considering calls to drop 'totality of circumstances' test and to clarify that mere knowledge of unapproved use does not constitute evidence the use was intended.

You may also be interested in...



US FDA’s First Amendment Defense

Before taking over the US health department, Alex Azar helped bring landmark litigation challenging the scope of FDA’s regulatory authority under the First Amendment. Now his tenure is ending with a First Amendment defense of the agency.

What Does Rachel Sherman Think About Top FDA Regulatory Issues?

Speaking at the BIO CEO & Investor Conference, US agency's No. 2 official talks about compassionate use, opioids, clinical trial design, and the agency's succession plan.

'Intended Use' Rule: US FDA May Toss Its 'Totality Of Evidence' Standard

Pharma and device industries had complained that rule is overbroad, violates the First Amendment and would increase company exposure to liability.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel